GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Debt-to-Revenue

Abionyx Pharma (XPAR:ABNX) Debt-to-Revenue : 0.68 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Abionyx Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.82 Mil. Abionyx Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.58 Mil. Abionyx Pharma's annualized Revenue for the quarter that ended in Dec. 2023 was €5.02 Mil. Abionyx Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.67.


Abionyx Pharma Debt-to-Revenue Historical Data

The historical data trend for Abionyx Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Debt-to-Revenue Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A 7.35 0.76 0.73

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 0.85 0.77 1.00 0.68

Competitive Comparison of Abionyx Pharma's Debt-to-Revenue

For the Biotechnology subindustry, Abionyx Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Debt-to-Revenue falls into.



Abionyx Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Abionyx Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.815 + 2.575) / 4.64
=0.73

Abionyx Pharma's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.815 + 2.575) / 5.024
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Abionyx Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Abionyx Pharma (XPAR:ABNX) Business Description

Traded in Other Exchanges
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines